Leukapheresis and Hyperleukocytosis, Past and Future

References

• Okafor C, Ward DM, Mokrzycki MH, Weinstein R, Clark P, Balogun RA. Introduction and overview of therapeutic apheresis. J Clin Apher. 2010;25(5):240–249. doi:10.1002/jca.20247
   PubMed Web of Science ®Google Scholar
• Tanaka T, Yamamoto T, Sawada K, Sacco R. Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy? Expert Rev Gastroenterol Hepatol. 2017;11(8):749–758. doi:10.1080/17474124.2017.1341309
   PubMed Web of Science ®Google Scholar
• Rowe JM, Lichtman MA. Hyperleukocytosis and leukostasis: common features of childhood chronic myelogenous leukemia. Blood. 1984;63(5):1230–1234. doi:10.1182/blood.V63.5.1230.1230
   PubMed Web of Science ®Google Scholar
• Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M. Leukocytoreduction for acute leukemia. Ther Apheresis. 2002;6(1):15–23. doi:10.1046/j.1526-0968.2002.00402.x
   PubMedGoogle Scholar
• Buresh A, Perentesis J, Rimsza L, et al. Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia. Leukemia. 2005;19(2):308–310. doi:10.1038/sj.leu.2403569
   PubMed Web of Science ®Google Scholar
• Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120(10):1993–2002. doi:10.1182/blood-2012-04-424440
   PubMed Web of Science ®Google Scholar
• Ali AM, Mirrakhimov AE, Abboud CN, Cashen AF. Leukostasis in adult acute hyperleukocytic leukemia: a clinician’s digest. Hematol Oncol. 2016;34(2):69–78. doi:10.1002/hon.2292
   PubMed Web of Science ®Google Scholar
• Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res. 2014;38(4):460–468. doi:10.1016/j.leukres.2014.01.004
   PubMed Web of Science ®Google Scholar
• Stoecklein NH, Fischer JC, Niederacher D, Terstappen LW. Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution. Expert Rev Mol Diagn. 2016;16(2):147–164. doi:10.1586/14737159.2016.1123095
   PubMed Web of Science ®Google Scholar
• Fischer JC, Niederacher D, Topp SA, et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A. 2013;110(41):16580–16585. doi:10.1073/pnas.1313594110
   PubMed Web of Science ®Google Scholar
• Aqui N, O’Doherty U. Leukocytapheresis for the treatment of hyperleukocytosis secondary to acute leukemia. Hematol Am Soc Hematol Educ Prog. 2014;2014(1):457–460. doi:10.1182/asheducation-2014.1.457
   PubMed Web of Science ®Google Scholar
• Tullis JL. Separation and purification of leukocytes and platelets. Blood. 1952;7(9):891–896. doi:10.1182/blood.V7.9.891.891
   PubMed Web of Science ®Google Scholar
• Batchelor WH, D’Hont M, Driscoll S, et al. New principle of closed system centrifugation. Science (New York, NY). 1956;124(3226):792–797. doi:10.1126/science.124.3226.792
   Google Scholar
• Buckner D, Eisel R, Perry S. Blood cell separation in the dog by continuous flow centrifugation. Blood. 1968;31(5):653–672. doi:10.1182/blood.V31.5.653.653
   PubMed Web of Science ®Google Scholar
• Djerassi I, Kim JS, Mitrakul C, Suvansri U, Ciesielka W. Filtration leukapheresis for separation and concentration of transfusable amounts of normal human granulocytes. J Med. 1970;1(6):358–364.
   PubMedGoogle Scholar
• Herzig GP, Root RK, Graw RG Jr. Granulocyte collection by continuous-flow filtration leukapheresis. Blood. 1972;39(4):554–567. doi:10.1182/blood.V39.4.554.554
   PubMed Web of Science ®Google Scholar
• Buckner D, Graw RG Jr, Eisel RJ, Henderson ES, Perry S. Leukapheresis by continuous flow centrifugation (CFC) in patients with chronic myelocytic leukemia (CML). Blood. 1969;33(2):353–369. doi:10.1182/blood.V33.2.353.353
   PubMed Web of Science ®Google Scholar
• Sethu P, Sin A, Toner M. Microfluidic diffusive filter for apheresis (leukapheresis). Lab Chip. 2006;6(1):83–89. doi:10.1039/B512049G
   PubMed Web of Science ®Google Scholar
• López-Pereira P, Sola Aparicio E, Vicuña Andrés I, et al. Retrospective comparison between COBE SPECTRA and SPECTRA OPTIA apheresis systems for hematopoietic progenitor cells collection for autologous and allogeneic transplantation in a single center. J Clin Apher. 2020;35(5):453–459. doi:10.1002/jca.21826
   PubMed Web of Science ®Google Scholar
• Duvall D. Therapeutic cytapheresis: too many platelets, too many white blood cells. J Clin Apher. 2011;26(1):47–52. doi:10.1002/jca.20266
   PubMed Web of Science ®Google Scholar
• Augustsson P, Karlsen JT, Su HW, Bruus H, Voldman J. Iso-acoustic focusing of cells for size-insensitive acousto-mechanical phenotyping. Nat Commun. 2016;7:11556. doi:10.1038/ncomms11556
   PubMed Web of Science ®Google Scholar
• Dykes J, Lenshof A, Astrand-Grundstrom IB, Laurell T, Scheding S. Efficient removal of platelets from peripheral blood progenitor cell products using a novel micro-chip based acoustophoretic platform. PLoS One. 2011;6(8):e23074. doi:10.1371/journal.pone.0023074
   PubMed Web of Science ®Google Scholar
• Nam J, Lim H, Kim D, Shin S. Separation of platelets from whole blood using standing surface acoustic waves in a microchannel. Lab Chip. 2011;11(19):3361–3364. doi:10.1039/c1lc20346k
   PubMed Web of Science ®Google Scholar
• Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39(1–2):1–18. doi:10.3109/10428190009053534
   PubMed Web of Science ®Google Scholar
• Altuntas F, Sari I, Kocyigit I, et al. Comparison of Plateletpheresis on the Fenwal Amicus and Fresenius Com Tec cell separators. Transfusion Med Hemother. 2008;35(5):368–373. doi:10.1159/000151351
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Rizzo D, Amato M, Riccardi R. Management of hyperleukocytosis. Curr Treat Options Oncol. 2016;17(2):7. doi:10.1007/s11864-015-0387-8
   PubMed Web of Science ®Google Scholar
• Hölig K, Moog R. Leukocyte depletion by therapeutic leukocytapheresis in patients with leukemia. Transfusion Med Hemother. 2012;39(4):241–245. doi:10.1159/000341805
   PubMed Web of Science ®Google Scholar
• Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012;26(3):117–122. doi:10.1016/j.blre.2012.01.003
   PubMed Web of Science ®Google Scholar
• Schulz M, Bialleck H, Thorausch K, et al. Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems. Transfusion. 2014;54(6):1622–1629. doi:10.1111/trf.12506
   PubMed Web of Science ®Google Scholar
• Andree KC, Mentink A, Zeune LL, et al. Toward a real liquid biopsy in metastatic breast and prostate cancer: diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). Int J Cancer. 2018;143(10):2584–2591. doi:10.1002/ijc.31752
   PubMed Web of Science ®Google Scholar
• Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171–354.
   PubMed Web of Science ®Google Scholar
• Eberhardson M, Marits P, Jones M, et al. Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. Clin immunol. 2013;149(1):73–82. doi:10.1016/j.clim.2013.05.021
   PubMed Web of Science ®Google Scholar
• Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. World J Gastroenterol. 2014;20(29):9699–9715. doi:10.3748/wjg.v20.i29.9699
   PubMed Web of Science ®Google Scholar
• Jin Y, Guo S, Cui Q, et al. A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia. Sci Rep. 2018;8(1):294. doi:10.1038/s41598-017-17534-4
   PubMed Web of Science ®Google Scholar
• Powell BL, Gregory BW, Evans JK, et al. Leukapheresis induced changes in cell cycle distribution and nucleoside transporters in patients with untreated acute myeloid leukemia. Leukemia. 1991;5(12):1037–1042.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Liseth K, Stamnesfet S, et al. Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfusion Med. 2013;23(6):397–406. doi:10.1111/tme.12067
   PubMed Web of Science ®Google Scholar
• Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children’s Oncology Group. Haematologica. 2012;97(11):1770–1773. doi:10.3324/haematol.2012.065490
   PubMed Web of Science ®Google Scholar
• Bojanic I, Mazic S, Rajic L, Jakovljevic G, Stepan J, Cepulic BG. Large volume leukapheresis is efficient and safe even in small children up to 15 kg body weight. Blood Transfusion = Trasfusione Del Sangue. 2017;15(1):85–92.
   PubMed Web of Science ®Google Scholar
• Galera P, Haynes S, Sulmasy P, et al. Physiological measurements corroborate symptomatic improvement after therapeutic leukapheresis in a pregnant woman with chronic myelogenous leukemia. J Clin Apher. 2016;31(4):393–397. doi:10.1002/jca.21410
   PubMed Web of Science ®Google Scholar
• Staley EM, Simmons SC, Feldman AZ, et al. Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature. Transfusion. 2018;58(2):456–460. doi:10.1111/trf.14448
   PubMed Web of Science ®Google Scholar
• Yellu M, Pinkard S, Ghose A, Medlin S. CML in pregnancy: a case report using leukapheresis and literature review. Transfusion Apheresis Sci. 2015;53(3):289–292.
   PubMed Web of Science ®Google Scholar
• Giammarco S, Chiusolo P, Piccirillo N, et al. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol. 2017;10(2):147–154. doi:10.1080/17474086.2017.1270754
   PubMed Web of Science ®Google Scholar
• Allon M. Current management of vascular access. Clin J Am Soc Nephrol. 2007;2(4):786–800. doi:10.2215/CJN.00860207
   PubMed Web of Science ®Google Scholar
• Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854. doi:10.1056/NEJMra0904569
   PubMed Web of Science ®Google Scholar
• Schlenke P, Frohn C, Steinhardt MM, Kirchner H, Kluter H. Clinically relevant hypokalaemia, hypocalcaemia, and loss of hemoglobin and platelets during stem cell apheresis. J Clin Apher. 2000;15(4):230–235. doi:10.1002/1098-1101(2000)15:4<230::AID-JCA3>3.0.CO;2-B
   PubMed Web of Science ®Google Scholar
• Punzel M, Kozlova A, Quade A, Schmidt AH, Smith R. Evolution of MNC and lymphocyte collection settings employing different Spectra Optia(®) Leukapheresis systems. Vox Sang. 2017;112(6):586–594. doi:10.1111/vox.12540
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–1891. doi:10.1182/blood-2008-04-150250
   PubMed Web of Science ®Google Scholar
• Rollig C, How EG. I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246–3252. doi:10.1182/blood-2014-10-551507
   PubMed Web of Science ®Google Scholar
• Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997;98(2):433–436. doi:10.1046/j.1365-2141.1997.1943011.x
   PubMed Web of Science ®Google Scholar
• Thiébaut A, Thomas X, Belhabri A, Anglaret B, Archimbaud E. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol. 2000;79(9):501–506. doi:10.1007/s002770000162
   PubMed Web of Science ®Google Scholar
• Giles FJ, Shen Y, Kantarjian HM, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma. 2001;42(1–2):67–73. doi:10.3109/10428190109097677
   PubMed Web of Science ®Google Scholar
• Chang MC, Chen TY, Tang JL, et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am J Hematol. 2007;82(11):976–980. doi:10.1002/ajh.20939
   PubMed Web of Science ®Google Scholar
• Choi MH, Choe YH, Park Y, et al. The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study. Transfusion. 2018;58(1):208–216. doi:10.1111/trf.14329
   PubMed Web of Science ®Google Scholar
• Nan X, Qin Q, Gentille C, et al. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center. Leuk Lymphoma. 2017;58(9):1–11. doi:10.1080/10428194.2016.1277386
   PubMed Web of Science ®Google Scholar
• Wong GC. Hyperleukocytosis in acute myeloid leukemia patients is associated with high 30-day mortality which is not improved with leukapheresis. Ann Hematol. 2015;94(12):2067–2068. doi:10.1007/s00277-015-2472-2
   PubMed Web of Science ®Google Scholar
• Bug G, Anargyrou K, Tonn T, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion. 2007;47(10):1843–1850. doi:10.1111/j.1537-2995.2007.01406.x
   PubMed Web of Science ®Google Scholar
• Pastore F, Pastore A, Wittmann G, Hiddemann W, Spiekermann K. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One. 2014;9(4):e95062. doi:10.1371/journal.pone.0095062
   PubMed Web of Science ®Google Scholar
• Stahl M, Shallis RM, Wei W, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020;34(12):3149–3160. doi:10.1038/s41375-020-0783-3
   PubMed Web of Science ®Google Scholar
• Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Rev Hematol. 2020;13(5):489–499. doi:10.1080/17474086.2020.1751609
   PubMed Web of Science ®Google Scholar
• Sietsma H, Kamps WA, Dontje B, et al. Leukemia-induced bone marrow depression: effects of gangliosides on erythroid cell production. Int J Cancer. 1999;82(1):92–97. doi:10.1002/(SICI)1097-0215(19990702)82:1<92::AID-IJC16>3.0.CO;2-J
   PubMed Web of Science ®Google Scholar
• Shahrabi S, Behzad MM, Jaseb K, Saki N. Thrombocytopenia in leukemia: pathogenesis and prognosis. Histol Histopathol. 2018;33(9):895–908.
   PubMed Web of Science ®Google Scholar
• Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28(3):145–284. doi:10.1002/jca.21276
   PubMed Web of Science ®Google Scholar